TY - JOUR
T1 - Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth
AU - Buzzai, Monica
AU - Jones, Russell G.
AU - Amaravadi, Ravi K.
AU - Lum, Julian J.
AU - DeBerardinis, Ralph J.
AU - Zhao, Fangping
AU - Viollet, Benoit
AU - Thompson, Craig B.
PY - 2007/7/15
Y1 - 2007/7/15
N2 - The effect of the antidiabetic drug metformin on tumor growth was investigated using the paired isogenic colon cancer cell lines HCT116 p53 +/+ and HCT116 p53-/-. Treatment with metformin selectively suppressed the tumor growth of HCT116 p53-/- xenografts. Following treatment with metformin, we detected increased apoptosis in p53 -/- tumor sections and an enhanced susceptibility of p53 -/- cells to undergo apoptosis in vitro when subject to nutrient deprivation. Metformin is proposed to function in diabetes treatment as an indirect activator of AMP-activated protein kinase (AMPK). Treatment with AICAR, another AMPK activator, also showed a selective ability to inhibit p53 -/- tumor growth in vivo. In the presence of either of the two drugs, HCT116 p53+/+ cells, but not HCT116 p53-/- cells, activated autophagy. A similar p53-dependent induction of autophagy was observed when nontransformed mouse embryo fibroblasts were treated. Treatment with either metformin or AICAR also led to enhanced fatty acid β-oxidation in p53+/+ MEFs, but not in p53-/- MEFs. However, the magnitude of induction was significantly lower in metformin-treated cells, as metformin treatment also suppressed mitochondrial electron transport. Metformin-treated cells compensated for this suppression of oxidative phosphorylation by increasing their rate of glycolysis in a p53-dependent manner. Together, these data suggest that metformin treatment forces a metabolic conversion that p53-/- cells are unable to execute. Thus, metformin is selectively toxic to p53-deficient cells and provides a potential mechanism for the reduced incidence of tumors observed in patients being treated with metformin.
AB - The effect of the antidiabetic drug metformin on tumor growth was investigated using the paired isogenic colon cancer cell lines HCT116 p53 +/+ and HCT116 p53-/-. Treatment with metformin selectively suppressed the tumor growth of HCT116 p53-/- xenografts. Following treatment with metformin, we detected increased apoptosis in p53 -/- tumor sections and an enhanced susceptibility of p53 -/- cells to undergo apoptosis in vitro when subject to nutrient deprivation. Metformin is proposed to function in diabetes treatment as an indirect activator of AMP-activated protein kinase (AMPK). Treatment with AICAR, another AMPK activator, also showed a selective ability to inhibit p53 -/- tumor growth in vivo. In the presence of either of the two drugs, HCT116 p53+/+ cells, but not HCT116 p53-/- cells, activated autophagy. A similar p53-dependent induction of autophagy was observed when nontransformed mouse embryo fibroblasts were treated. Treatment with either metformin or AICAR also led to enhanced fatty acid β-oxidation in p53+/+ MEFs, but not in p53-/- MEFs. However, the magnitude of induction was significantly lower in metformin-treated cells, as metformin treatment also suppressed mitochondrial electron transport. Metformin-treated cells compensated for this suppression of oxidative phosphorylation by increasing their rate of glycolysis in a p53-dependent manner. Together, these data suggest that metformin treatment forces a metabolic conversion that p53-/- cells are unable to execute. Thus, metformin is selectively toxic to p53-deficient cells and provides a potential mechanism for the reduced incidence of tumors observed in patients being treated with metformin.
UR - http://www.scopus.com/inward/record.url?scp=34547114031&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547114031&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-06-4447
DO - 10.1158/0008-5472.CAN-06-4447
M3 - Article
C2 - 17638885
AN - SCOPUS:34547114031
SN - 0008-5472
VL - 67
SP - 6745
EP - 6752
JO - Cancer research
JF - Cancer research
IS - 14
ER -